文献速递前列腺癌

转移性去势敏感性前列腺癌治疗的疗效与安全性:纳入ARANOTE最终数据的综合网状Meta分析

Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-12-09

该网状Meta分析纳入ARANOTE III期试验最终数据,比较转移性去势敏感性前列腺癌(mCSPC)不同联合方案的疗效与安全性。结果显示DAR+DOC+ADT在PFS和OS上均排名最高,DAR+ADT安全性最佳且疗效与其他双药联合相当。

要点

  • DAR+DOC+ADT在PFS(HR 0.27)和OS(HR 0.52)上均显示最高疗效排名。
  • 含多西他赛方案3-5级不良事件更常见,ABI+DOC+ADT风险最高。
  • DAR+ADT在所有安全性结局上排名最佳,与ADT单药相当。

核心结论

  • ARPI联合方案在OS和PFS上均优于ADT单药。
  • DAR+ADT疗效与其他双药联合相当,但安全性更优。

研究设计与样本

  • 网状Meta分析,纳入ARANOTE III期试验最终数据。
  • 评估PFS和OS,并分析3-5级不良事件、严重不良事件及因不良事件停药。
  • 采用亚组分析评估异质性,并进行类效应网状Meta分析。

主要发现

  • DAR+DOC+ADT的PFS HR为0.27(95% CrI: 0.18, 0.39),SUCRA为0.97。
  • DAR+DOC+ADT的OS HR为0.52(95% CrI: 0.43, 0.64),SUCRA为0.95。
  • 含多西他赛联合方案3-5级不良事件更频繁,ABI+DOC+ADT风险最高。
  • DAR+ADT在所有安全性结局上排名最佳,与其他双药联合相比更优,与ADT单药相当。

临床怎么用

  • 对于mCSPC患者,ARPI联合ADT较ADT单药可改善OS和PFS。
  • DAR+ADT可作为兼顾疗效与安全性的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the proven efficacy of androgen deprivation therapy (ADT) combined with androgen receptor pathway inhibitors (ARPIs) in metastatic castration-sensitive prostate cancer (mCSPC), many patients still receive ADT monotherapy due to safety concerns. This reliance on ADT monotherapy underscores the need for education on the comparative effectiveness and safety of available therapies versus ADT. We evaluated the efficacy and safety of alternative treatment combinations, incorporating final data from the recent ARANOTE Phase III trial. METHODS: We conducted network meta-analysis (NMA) to evaluate progression-free survival (PFS) and overall survival (OS), incorporating heterogeneity assessment through subgroup analyses. Additionally, we performed a separate class effect NMA. We analysed grade 3-5 adverse events (AEs), serious AEs, and discontinuation due to AEs. We estimated hazard ratios (HRs) for efficacy, rate ratios (RRs) for safety, 95% credible intervals (CrI), and the surface under the cumulative ranking area (SUCRA) to rank treatments by efficacy and safety. RESULTS: Darolutamide (DAR) + docetaxel (DOC) + ADT showed the highest effect size [HR of 0.27 (95% CrI: 0.18, 0.39)] and the highest ranking (SUCRA: 0.97) across the base case and several subgroups on the PFS outcome. On OS, DAR + DOC + ADT similarly achieved the lowest HR of 0.52 (0.43, 0.64) and the highest ranking (SUCRA of 0.95). Safety analyses showed that grade 3-5 AEs were more frequent with docetaxel combinations, with ABI + DOC + ADT having the highest risk of grade 3-5 AEs. DAR + ADT was ranked best on all safety outcomes, outperforming other doublets and comparable to ADT monotherapy. CONCLUSIONS: This NMA supports the superior efficacy of ARPI combinations against ADT monotherapy, for both OS and PFS. While DAR + ADT demonstrated comparable efficacy to other doublet combinations, it offered a superior safety profile, making it an effective and safe option for managing patients with mCSPC.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Shore N, Morgans AK, Paracha N, et al. Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data. Prostate Cancer Prostatic Dis. 2025. PMID: 41366131. doi:10.1038/s41391-025-01054-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。